Development of a Scalable Synthetic Route and a Crystal Morphology Characterization Method for the PDE4B Inhibitor HY-072808

An improved synthesis of HY-072808 (1), a highly potent and selective PDE4B inhibitor developed as a clinical candidate, is reported, achieving an overall yield of 42.9% and a purity of 99.98%. Starting from readily available and inexpensive 4-(trifluoromethyl)aniline (10) and 2-bromo-5-hydroxybenzaldehyde (5), HY-072808 was effectively and conveniently synthesized without chromatographic purification in any steps. Key improvements include enhanced control over impurity formation, increased productivity of the SNAr reaction, efficient purification of the product through acidification, effective removal of palladium via recrystallization, and a reliable method for identifying the crystal morphology. This process has been successfully scaled up to produce over 3 kg of HY-072808.